pSivida’s financial results for the third quarter were similar to results reported for the third quarter a year ago, according to a press release.Quarterly net loss was reported at $5 million, or $0.15 per share, compared with a net loss of $5 million, or $0.17 per share, a year ago.
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that Jarett Fenton has been appointed as its Chief Financial Officer effective yesterday. As Chief Financial Officer, Mr….
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek announced that David P. Southwell, President and Chief Executive Officer of Inotek, will participate in a fireside chat at the JMP Securities 2016 Life Sciences Conference.
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in Rocket 4, the Company’s Phase 3 clinical trial for RhopressaTM (netarsudil ophthalmic solution) 0.02% intended to satisfy filing requirements in Europe. RhopressaTM is a novel once-daily eye drop being tested for its ability to l
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting, William B. Trattler, MD, discusses available preoperative testing for dry eye patients undergoing ocular surgery.